HeartFlow, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.5M
Doctors Paid
9,758
Transactions
24,704
2024 Total
$1.9M
Payment Breakdown by Category
Research$9.2M (68.1%)
Consulting$1.9M (13.7%)
Food & Beverage$1.2M (8.7%)
Travel$296,831 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.2M | 603 | 68.1% |
| Consulting Fee | $1.9M | 647 | 13.7% |
| Food and Beverage | $1.2M | 21,859 | 8.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $787,647 | 465 | 5.8% |
| Travel and Lodging | $296,831 | 1,080 | 2.2% |
| Education | $148,750 | 24 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $21,000 | 10 | 0.2% |
| Grant | $13,000 | 4 | 0.1% |
| Entertainment | $654.34 | 7 | 0.0% |
| Honoraria | $249.80 | 4 | 0.0% |
| Gift | $83.55 | 1 | 0.0% |
Payments by Type
Research
$9.2M
524 transactions
General
$4.3M
24,101 transactions
Ownership
$0
79 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | $3.2M | 0 | 133 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 424 PRECISE | $2.0M | 0 | 187 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 438 JACS | $890,682 | 0 | 29 |
| Prospective Randomized Trial of Optimal Evaluation of Suspected Coronary Artery Disease | $654,643 | 0 | 5 |
| RetrospectivE study of FFRCT compared to mFFR and CTA In the post-market ENvironmEnt | $356,268 | 0 | 8 |
| Precise Study | $267,144 | 0 | 32 |
| Evaluation of FFRCT to improve efficacy and efficiency of management of Patients With Acute Chest Pain as compared to anatomic CCTA and Standard of Care | $245,460 | 0 | 3 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 447 REVEALPLAQUE | $184,335 | 0 | 21 |
| REFINE Cardiovascular Imaging Core Lab. | $183,688 | 0 | 1 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 448 MGH Type 2 MI | $168,551 | 0 | 6 |
| PRECISE, C6000136 Protocol #CP-907-001-A PI: Victor Marinnescu, MD | $160,300 | 0 | 7 |
| AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | $114,550 | 0 | 17 |
| PRECISE, C6000148 Protocol #CP-907-001-A PI: Sorin Danciu, MD, | $102,250 | 0 | 1 |
| Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) | $95,895 | 0 | 21 |
| Promise - CT - FFR Cost Effectiveness Analysis | $89,560 | 0 | 1 |
| SPECT vs CT vs. FFRCT: Diagnostic accuracy (using FFRCT as gold standard) | $78,576 | 0 | 4 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 437 P3 | $69,500 | 0 | 1 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 442 FFRct ACP | $64,800 | 0 | 2 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 443 ADVANCE-ED | $52,640 | 0 | 8 |
| "The AFFECTS Study: Assessment of Fractional Flow reservE Computed Tomography versus Single photon emission computed tomography in the diagnosis of hemodynamically significant coronary artery disease " | $46,464 | 0 | 5 |
| The AFFECTS Study: Assessment of Fractional Flow reservE Computed Tomography versus | $42,079 | 0 | 5 |
| 100 Analysis : 200 FFRct Analysis : 201 FFRct (Default) | $30,150 | 0 | 2 |
| PRECISE, C6000136 Protocol #CP-907-001-A PI: Victor Marinescu, MD, | $29,550 | 0 | 3 |
| Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE | $12,848 | 0 | 3 |
| PRECISE CP-907-001-A - IRB FEE | $12,500 | 0 | 1 |
| Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularizaton -Protocol CP-907-001-A | $12,094 | 0 | 3 |
| PRECISE Protocol #CP-907-001-A | $11,000 | 0 | 1 |
| Precise Study -CP-907-001-A | $7,813 | 0 | 2 |
| CP-907-001-A PRECISE | $7,700 | 0 | 1 |
| PRECISE CP-907-001-A | $6,350 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 6
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Joseph Lash, Md, MD | Cardiovascular Disease | Louisville, KY | $1,997 | $0 |
| Ivan Ayala, Md, MD | Cardiovascular Disease | Plantation, FL | $1,994 | $0 |
| Dr. Donnevan Blake, M.d, M.D | Cardiovascular Disease | Green Bay, WI | $1,987 | $0 |
| Dr. Evans Pappas, Md, MD | Cardiovascular Disease | Naperville, IL | $1,978 | $0 |
| Michael Walls, Md, MD | Cardiovascular Disease | Indianapolis, IN | $1,978 | $0 |
| Dr. Faisal Nabi, M.d, M.D | Cardiovascular Disease | Houston, TX | $1,941 | $0 |
| David Harding, M.d, M.D | Interventional Cardiology | Greensboro, NC | $1,939 | $0 |
| Christopher Morgan, D.o, D.O | Internal Medicine | Beaver, PA | $1,939 | $0 |
| Dr. Juan Lopez-Mattei, M.d, M.D | Cardiovascular Disease | Fort Myers, FL | $1,916 | $0 |
| Ethiraj Raj, Md, MD | Specialist | Flint, MI | $1,910 | $0 |
| Jack Xu | Internal Medicine | Winston Salem, NC | $1,894 | $0 |
| Mithun Chakravarthy, Md, MD | Cardiovascular Disease | Pittsburgh, PA | $1,844 | $0 |
| Neil Agrawal, M.d, M.D | Cardiovascular Disease | Tulsa, OK | $1,835 | $0 |
| James Orford, M.d, M.D | Cardiovascular Disease | Murray, UT | $1,830 | $0 |
| Travis Tagami, Do, DO | Internal Medicine | Englewood, CO | $1,827 | $0 |
| Robert Carlucci, Md, MD | Physician Assistant | Staten Island, NY | $1,822 | $0 |
| Dr. Daniel Krause, Do, DO | Cardiovascular Disease | Wausau, WI | $1,800 | $0 |
| Dr. Chikako Ono, Md, MD | Cardiovascular Disease | Milwaukee, WI | $1,788 | $0 |
| Dr. Andrew Einstein, M.d., Ph.d, M.D., PH.D | Cardiovascular Disease | New York, NY | $1,775 | $0 |
| Dr. Richard Begg, Md, MD | Cardiovascular Disease | Butler, PA | $1,764 | $0 |
| Ren Zhang, M.d, M.D | Cardiovascular Disease | Abilene, TX | $1,750 | $0 |
| Katherine Kaproth-Joslin, Md/Phd, MD/PHD | Diagnostic Radiology | Rochester, NY | $1,737 | $0 |
| Victor Marinescu, Md, MD | Internal Medicine | Naperville, IL | $1,718 | $0 |
| Dr. David Buck, D.o, D.O | Internal Medicine | Bradenton, FL | $1,716 | $0 |
| Dr. Kazue Okajima | Internal Medicine | El Paso, TX | $1,705 | $0 |
About HeartFlow, Inc.
HeartFlow, Inc. has made $13.5M in payments to 9,758 healthcare providers, recorded across 24,704 transactions in the CMS Open Payments database. In 2024, the company paid $1.9M. The top product by payment volume is FFRct ($9.1M).
Payments were distributed across 126 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($2.2M to 3,323 doctors).
Payment categories include: Food & Beverage ($1.2M), Consulting ($1.9M), Research ($9.2M), Travel & Lodging ($296,831).
HeartFlow, Inc. is associated with 1 products in the CMS Open Payments database.